Autoři: Elisé G. Kaboré aff001; Charles Guenancia aff002; Ines Vaz-Luis aff003; Antonio Di Meglio aff003; Barbara Pistilli aff003; Charles Coutant aff004; Paul Cottu aff005; Anne Lesur aff006; Thierry Petit aff007; Florence Dalenc aff008; Philippe Rouanet aff009; Antoine Arnaud aff010; Olivier Arsene aff011; Mahmoud Ibrahim aff012; Johanna Wassermann aff013; Geneviève Boileau-Jolimoy aff014; Anne-Laure Martin aff015; Jérôme Lemonnier aff015; Fabrice André aff003; Patrick Arveux aff001 Působiště autorů: “Health across Generations” Team, Inserm U1018, Centre for Research in Epidemiology and Population Health (CESP), Villejuif, France aff001; Cardiology Department, University Hospital Dijon Bourgogne, Dijon, France aff002; Institut Gustave Roussy, Villejuif, France aff003; Centre Georges-François Leclerc, Dijon, France aff004; Institut Curie, Paris, France aff005; Centre Alexis Vautrin, Vandoeuvre les Nancy, France aff006; Centre Paul Strauss, Strasbourg, France aff007; Institut Claudius Regaud, Toulouse, France aff008; Institut du Cancer de Montpellier, Montpellier, France aff009; Clinique Sainte Catherine, Avignon, France aff010; Centre Hospitalier de Blois, Blois, France aff011; Centre Hospitalier Régional d’Orléans, Orléans, France aff012; AP-HP Pitié-Salpêtrière, Paris, France aff013; Polyclinique du Parc Drevon, Dijon, France aff014; Unicancer, Paris, France aff015 Vyšlo v časopise: Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. PLoS Med 16(12): e32767. doi:10.1371/journal.pmed.1002989 Kategorie: Research Article doi: https://doi.org/10.1371/journal.pmed.1002989
In patients treated with cardiotoxic chemotherapies, the presence of cardiovascular risk factors and previous cardiac disease have been strongly correlated to the onset of cardiotoxicity. The influence of overweight and obesity as risk factors in the development of treatment-related cardiotoxicity in breast cancer (BC) was recently suggested. However, due to meta-analysis design, it was not possible to take into account associated cardiac risk factors or other classic risk factors for anthracycline (antineoplastic antibiotic) and trastuzumab (monoclonal antibody) cardiotoxicity.
Using prospective data collected from 2012–2014 in the French national multicenter prospective CANTO (CANcer TOxicities) study of 26 French cancer centers, we aimed to examine the association of body mass index (BMI) and cardiotoxicity (defined as a reduction in left ventricular ejection fraction [LVEF] > 10 percentage points from baseline to LVEF < 50%). In total, 929 patients with stage I–III BC (mean age 52 ± 11 years, mean BMI 25.6 ± 5.1 kg/m2, 42% with 1 or more cardiovascular risk factors) treated with anthracycline (86% epirubicin, 7% doxorubicin) and/or trastuzumab (36%), with LVEF measurement at baseline and at least 1 assessment post-chemotherapy were eligible in this interim analysis. We analyzed associations between BMI and cardiotoxicity using multivariate logistic regression. At baseline, nearly 50% of the study population was overweight or obese. During a mean follow-up of 22 ± 2 months following treatment completion, cardiotoxicity occurred in 29 patients (3.2%). The obese group was more prone to cardiotoxicity than the normal-weight group (9/171 versus 8/466; p = 0.01). In multivariate analysis, obesity (odds ratio [OR] 3.02; 95% CI 1.10–8.25; p = 0.03) and administration of trastuzumab (OR 12.12; 95% CI 3.6–40.4; p < 0.001) were independently associated with cardiotoxicity. Selection bias and relatively short follow-up are potential limitations of this national multicenter observational cohort.
In BC patients, obesity appears to be associated with an important increase in risk-related cardiotoxicity (CANTO, ClinicalTrials.gov registry ID: NCT01993498).
ClinicalTrials.gov NCT01993498.
Body Mass Index – Breast cancer – Cancer chemotherapy – Cancer risk factors – Cancer treatment – Hypertension – Obesity
1. Rosa GM, Gigli L, Tagliasacchi MI, Di Iorio C, Carbone F, Nencioni A, et al. Update on cardiotoxicity of anti-cancer treatments. Eur J Clin Invest. 2016;46 : 264–84. doi: 10.1111/eci.12589 26728634
2. Volkova M, Russell R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7 : 214–20. doi: 10.2174/157340311799960645 22758622
3. Santoni M, Guerra F, Conti A, Lucarelli A, Rinaldi S, Belvederesi L, et al. Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies. Cancer Treat Rev. 2017;59 : 123–31. doi: 10.1016/j.ctrv.2017.07.006 28818671
4. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133 : 1104–14. doi: 10.1161/CIRCULATIONAHA.115.020406 26976915
5. Majed B, Moreau T, Asselain B, Curie Institute Breast Cancer Group. Overweight, obesity and breast cancer prognosis: optimal body size indicator cut-points. Breast Cancer Res Treat. 2009;115 : 193–203. doi: 10.1007/s10549-008-0065-7 18546073
6. Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat. 2008;111 : 329–42. doi: 10.1007/s10549-007-9785-3 17939036
7. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4 : 579–91. doi: 10.1038/nrc1408 15286738
8. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371 : 569–78. doi: 10.1016/S0140-6736(08)60269-X 18280327
9. Guenancia C, Lefebvre A, Cardinale D, Yu AF, Ladoire S, Ghiringhelli F, et al. Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis. J Clin Oncol. 2016;34 : 3157–65. doi: 10.1200/JCO.2016.67.4846 27458291
10. Mitra MS, Donthamsetty S, White B, Mehendale HM. High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity. Toxicol Appl Pharmacol. 2008;231 : 413–22. doi: 10.1016/j.taap.2008.05.006 18674790
11. Guenancia C, Hachet O, Aboutabl M, Li N, Rigal E, Cottin Y, et al. Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity. Cancer Chemother Pharmacol. 2016;77 : 777–85. doi: 10.1007/s00280-016-2995-9 26914236
12. Vaz-Luis I, Cottu P, Mesleard C, Martin AL, Dumas A, Dauchy S, et al. UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO). ESMO Open. 2019;4:e000562. doi: 10.1136/esmoopen-2019-000562 31555487
13. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37 : 2768–801. doi: 10.1093/eurheartj/ehw211 27567406
14. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854 : 1–452. 8594834
15. Armenian S, Lacchetti C, Barac A, Carver J, Constine L, Denduluri N. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35 : 893–911. doi: 10.1200/JCO.2016.70.5400 27918725
16. McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31 : 63–75. doi: 10.1007/s10557-016-6711-0 28185035
17. Colombo A, Sandri MT, Salvatici M, Cipolla CM, Cardinale D. Cardiac complications of chemotherapy: role of biomarkers. Curr Treat Options Cardiovasc Med. 2014;16 : 313. doi: 10.1007/s11936-014-0313-6 24771223
18. Kongbundansuk S, Hundley WG. Noninvasive imaging of cardiovascular injury related to the treatment of cancer. JACC Cardiovasc Imaging. 2014;7 : 824–38. doi: 10.1016/j.jcmg.2014.06.007 25124015
19. Agmon Nardi I, Iakobishvili Z. Cardiovascular risk in cancer survivors. Curr Treat Options Cardiovasc Med. 2018;20 : 47. doi: 10.1007/s11936-018-0645-8 29705862
20. Linschoten M, Teske AJ, Cramer MJ, van der Wall E, Asselbergs FW. Chemotherapy-related cardiac dysfunction: a systematic review of genetic variants modulating individual risk. Circ Genom Precis Med. 2018;11:e001753. doi: 10.1161/CIRCGEN.117.001753 29557343
21. Kenchaiah S, Sesso HD, Gaziano JM. Body mass index and vigorous physical activity and the risk of heart failure among men. Circulation. 2009;119 : 44–52. doi: 10.1161/CIRCULATIONAHA.108.807289 19103991
22. Kenchaiah S, Chesebro JH. The epidemiologic association between obesity and heart failure. Am Coll Cardiol Ext Learn. 2017;49 : 4–6. 29527015
23. Hirayama A, Goto T, Shimada YJ, Faridi MK, Camargo CA, Hasegawa K. Association of obesity with severity of heart failure exacerbation: a population-based study. J Am Heart Assoc. 2018;7:e008243. doi: 10.1161/JAHA.117.008243 29545263
24. Guglin M, Munster P, Fink A, Krischer J. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: a rationale and design of a randomized clinical trial. Am Heart J. 2017;188 : 87–92. doi: 10.1016/j.ahj.2017.03.010 28577685
25. Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92 : 98–107. doi: 10.1016/j.metabol.2018.10.011 30399375
26. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11 : 85–97. doi: 10.1038/nri2921 21252989
Zvyšte si kvalifikaci online z pohodlí domova
Nemáte účet? Registrujte se
Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.
